Table 3 Univariate analyses of outcomes according to clinicopathological variables and rad-CD73
Disease-specific survival | Time-to-recurrence | |||
|---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | |
Age at hepatectomy (≤ 65 vs > 65 years) | 0.88 (0.56–1.39) | 0.58 | 0.70 (0.46–1.07) | 0.10 |
Gender (male vs female) | 1.16 (0.72–1.84) | 0.54 | 0.97 (0.63–1.51) | 0.91 |
Number of metastases (single vs multiple) | 1.37 (0.87–2.16) | 0.17 | 1.50 (0.98–2.29) | 0.06 |
Diameter of largest metastasis (≤ 5 vs > 5 cm) | 1.43 (0.87–2.37) | 0.16 | 1.44 (0.90–2.30) | 0.13 |
Disease-free interval < 12 months (no vs yes) | 1.52 (0.90–2.58) | 0.12 | 1.43 (0.89–2.28) | 0.14 |
CEA level (≤ 200 vs > 200 ng/mL) | 4.38 (1.34–14.38) | 0.01 | 5.12 (1.57–16.62) | 0.01 |
Tertiary lymphoid structure (absent vs present) | 0.86 (0.43–1.73) | 0.68 | 0.95 (0.49–1.84) | 0.88 |
Liver resection margin (negative vs positive for cancer cells) | 1.06 (0.50–2.22) | 0.89 | 1.10 (0.55–2.18) | 0.79 |
Necrosis (≤ 25 vs > 25%) | 1.18 (0.63–2.18) | 0.61 | 1.02 (0.57–1.80) | 0.96 |
Primary tumor (left vs right) | 0.79 (0.48–1.28) | 0.33 | 0.87 (0.55–1.37) | 0.54 |
pT category (T1-T2-T3 vs T4) | 2.05 (1.16–3.59) | 0.01 | 2.51 (1.45–4.34) | < 0.005 |
pN category (N0 vs N +) | 1.25 (0.77–2.02) | 0.37 | 1.30 (0.84–2.01) | 0.25 |
Pre-operative chemotherapy (no vs yes) | 1.73 (0.91–3.27) | 0.09 | 1.73 (0.99–3.03) | 0.05 |
Tumor regression grade (1–2 vs 3–4–5) | 0.84 (0.44–1.61) | 0.61 | 1.31 (0.68–2.52) | 0.43 |
KRAS status (wild-type vs mutated) | 1.18 (0.61–2.28) | 0.63 | 2.23 (1.14–4.37) | 0.02 |
Clinical Risk Score (0–1–2 vs 3–4–5) | 1.60 (1.01–2.51) | 0.04 | 1.97 (1.29–3.03) | < 0.005 |
rad-CD73 (low vs high) | 1.80 (1.08–3.00) | 0.02 | 1.84 (1.15–2.95) | 0.01 |